The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.
- Foam 2%
- Cream 2% in an aqueous vehicle
- Tablets 200 mg
- Shampoo 2% in an aqueous suspension
- Shampoo 1%
- Gel 2%
Impairs synthesis of ergosterol, allowing increased permeability in fungal cell membrane and leakage of cellular components.
C max is approximately 3.5 mcg/mL (with a 200 mg oral dose taken with a meal). T max is 1 to 2 h. Requires acidity for dissolution and absorption. Absorbed in the GI.
Approximately 99% protein bound (in vitro), mainly to the albumin fraction. Only a negligible proportion reaches the cerebrospinal fluid.
Major metabolic pathways are oxidation and degradation of the imidazole and piperazine rings, oxidative O-dealkylation, and aromatic hydroxylation. It is converted into several inactive metabolites.
Approximately 13% of dose is excreted in urine; 2% to 4% is unchanged drug. The major route of excretion is through the bile into the intestinal tract. Plasma elimination is biphasic with a half-life of 2 h during the first 10 h, and a half-life of 8 h after 10 h.
Indications and UsageOral
Treatment of susceptible systemic and cutaneous fungal infections.Foam/Gel
Treatment of seborrheic dermatitis in immunocompetent adults and children 12 y of age and older.Cream
Cutaneous candida; tinea corporis; tinea cruris; tinea pedis; tinea versicolor; seborrheic dermatitis ( Kuric ).Shampoo 1%
Scaling due to dandruff.Shampoo 2%
Oral ketoconazole coadministered with astemizole, cisapride, terfenadine, and/or triazolam; hypersensitivity to any components.
Dosage and AdministrationAdults
PO 200 to 400 mg daily for 1 wk to 6 mo depending on infection.Children 2 y of age and older
PO A small number of children older than 2 y of age have been treated with 3.3 to 6.6 mg/kg daily for 1 wk to 6 mo depending on infection.Adults and Children 12 y of age and older
Apply to affected and immediate surrounding areas every day for 2 wk (candidiasis, tinea cruris, tinea corporis, and tinea versicolor) or 6 wk (tinea pedis). For seborrheic dermatitis, apply to affected areas twice daily for 4 wk or until clinical clearing ( Kuric ).Foam
Apply to affected area(s) twice daily for 4 wk.Gel
Apply to affected area once daily for 2 wk.Shampoo 2%
Apply to affected area and a wide margin of surrounding area, lather, leave in place for 5 min, then rinse. One application only.Shampoo 1%
Apply to wet hair, lather, rinse thoroughly, and repeat. Use shampoo every 3 to 4 days for up to 8 wk.Foam
- Holding the container upright, dispense into cap of the can or other cool surface in an amount sufficient to cover affected area(s).
- Because the foam will begin to melt immediately upon contact with warm skin, do not dispense directly onto hands.
- Pick up small amounts of foam with fingertips and gently massage into affected area(s) until foam disappears.
- For hair-bearing areas, part hair and apply foam directly to the skin.
- Avoid contact with eyes and/or mucous membranes.
- Avoid contact with the eyes and/or mucous membranes.
Store at 68° to 77°F. Store Kuric cream below 77°F.Foam
Store at 68° to 77°F. Do not refrigerate. Do not expose container to heat or store at temperatures higher than 120°F. Do not store in direct sunlight. Contents are flammable and under pressure. Do not puncture or incinerate container.Gel
Store at 59° to 86°F.Shampoo 1%
Store at 35° to 86°F. Protect from light.Shampoo 2%
Store below 77°F. Protect from light.Tablets
Store at controlled room temperature (59° to 77°F) in tightly closed container. Protect from moisture.
Rare cases of disulfiram-like reactions to alcohol have been reported.Alfuzosin
Increased alfuzosin levels; avoid concomitant use.Almotriptan, eletriptan
Do not take almotriptan within 7 days of ketoconazole; do not take eletriptan within 72 h of ketoconazole.Antacids
Increased gastric pH may inhibit ketoconazole absorption; separate administration by at least 2 h.Aripiprazole
Plasma levels may be elevated by ketoconazole; reduce aripiprazole dose by 50% during coadministration.Benzodiazepines (eg, midazolam)
Plasma levels of benzodiazepines may be increased and prolonged.Bosentan, buspirone, carbamazepine, cinacalet, cyclophosphamide, cyclosporine, digoxin, felodipine, gefitinib, haloperidol, loratadine, methylprednisolone, nisoldipine, opioid analgesics (eg, fentanyl), protease inhibitors (eg, indinavir), quetiapine, quinidine, quinine, risperidone, sirolimus, solifenacin, sulfonylureas, tacrolimus, taxoids (eg, docetaxel), tolterodine, tricyclic antidepressants (eg, amitriptyline), venlafaxine, zolpidem
Plasma levels may be elevated by ketoconazole, increasing the risk of adverse reactions.Cisapride, conivaptan, eplerenone, ergot derivatives (eg, ergotamine), oral triazolam, pimozide, ranolazine
Plasma levels may be elevated by ketoconazole; coadministration with ketoconazole is contraindicated.Clopidogrel
Antiplatelet effect of clopidogrel may be inhibited.Corticosteroids
Increased bioavailability and decreased clearance of corticosteroid.Didanosine, histamine H 2 -receptor antagonists (eg, cimetidine), isoniazid, proton pump inhibitors (eg, omeprazole)
May decrease ketoconazole absorption.Dofetilide
Elevated plasma levels of dofetilide may increase the risk of life-threatening cardiac arrhythmia.HMG-CoA reductase inhibitors (eg, atorvastatin)
Plasma levels may be increased by ketoconazole; if coadministration cannot be avoided, carefully monitor patient for rhabdomyolysis and consider using pravastatin.Hydantoins
Metabolism of one or both drugs may be altered. Monitor the clinical response.Phosphodiesterase type-5 inhibitors (eg, sildenafil)
Plasma levels may be elevated by ketoconazole; reduce dose of phosphodiesterase.Rifampin
Decreased serum levels of either drug; avoid concomitant use.Theophylline
Decreased theophylline serum concentrations.Vinca alkaloids (eg, vinblastine)
Plasma levels may be elevated by ketoconazole; avoid coadministration.Warfarin
Increased anticoagulant effect.
Laboratory Test Interactions
None well documented.
Increased intracranial pressure, neuropsychiatric disturbances, paresthesia (postmarketing).Gel
Pruritus (2%); alopecia (postmarketing).
Nausea, vomiting (3%); abdominal pain (1%).
Oligospermia (with high doses).
Hepatic function impairment.
Pruritus, severe irritation, stinging; contact dermatitis (postmarketing).Foam
Photo-allergenicity (17%); application-site burning (10%); application-site reaction (6%).Gel
Application-site burning (4%).Shampoo 2%
Application-site reaction, dry skin, pruritus (3% or less).
When used orally, hepatotoxicity has been reported and included fatalities; use caution when coadministering with other hepatotoxic drugs.
Measure LFTs before starting treatment and at frequent intervals during treatment.
Category C .
Safety and efficacy not established.Foam/Gel/Shampoo 1%
Safety and efficacy not established in children younger than 12 y of age.
Cream contains sodium sulfite anhydrous, which may cause allergic-type reactions, including anaphylaxis.
Has occurred after the first dose.
Oral ketoconazole requires acid environment for dissolution and absorption.
May lower serum testosterone or suppress adrenal corticosteroid secretion.
Foam may cause contact sensitization, including photoallergenicity.
Oral ketoconazole coadministration with terfenadine, astemizole, or cisapride has led to prolongation of the QT interval, resulting in life-threatening arrhythmias, including torsades de pointes.
No data available.
- Advise patient to read the patient information leaflet before using product the first time and with each refill.
- Instruct patient that if a dose is missed, to take it as soon as possible. If several hours have passed or if it is close to the time of next dose, do not double the dose. Notify health care provider if more than 1 dose is missed.
- Advise patient not to take medication with antacids. If antacids are required, take ketoconazole 2 h before antacid.
- Emphasize importance of completing full course of therapy, even if signs and symptoms resolve. Advise patient that maintenance therapy may be required for chronic infections.
- Instruct patient to report the following symptoms to health care provider: abdominal pain, dark urine, diarrhea, fatigue, fever, loss of appetite, nausea, pale stools, vomiting, yellowing of skin.
- Advise patient that drug may cause drowsiness and to use caution while driving or performing other tasks requiring mental alertness.
- Instruct patient not to take OTC medications, including antihistamines, without consulting health care provider.
- Inform patient that product is for external use only.
- Advise patients that product may be irritating to mucous membranes and to avoid contact with eyes, nostrils, and mouth.
- Instruct patients to wash hands after application.
- Instruct patient to notify health care provider if severe itching, irritation, or stinging occurs after application.
Copyright © 2009 Wolters Kluwer Health.